Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) traded up 10.1% on Monday . The stock traded as high as $0.21 and last traded at $0.20. 6,799,683 shares traded hands during trading, an increase of 128% from the average session volume of 2,978,440 shares. The stock had previously closed at $0.18.
Separately, Zacks Investment Research lowered Argos Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 14th. One analyst has rated the stock with a sell rating and three have assigned a hold rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $4.13.
The company’s market capitalization is $10.14 million. The company has a 50-day moving average of $0.19 and a 200-day moving average of $0.33.
Argos Therapeutics (NASDAQ:ARGS) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.10 million. Argos Therapeutics had a negative return on equity of 1,532.49% and a negative net margin of 12,391.15%. Analysts forecast that Argos Therapeutics, Inc. will post ($1.19) earnings per share for the current fiscal year.
WARNING: “Argos Therapeutics, Inc. (ARGS) Trading 10.1% Higher” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/10/11/argos-therapeutics-inc-args-trading-10-1-higher.html.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.